keyword
MENU ▼
Read by QxMD icon Read
search

Febuxostat tumor lysis syndrome

keyword
https://www.readbyqxmd.com/read/28982910/febuxostat-as-a-prophylaxis-for-tumor-lysis-syndrome-in-children-with-hematological-malignancies
#1
Kenji Kishimoto, Ryoji Kobayashi, Daiki Hori, Hirozumi Sano, Daisuke Suzuki, Kunihiko Kobayashi
AIM: The aim of the present study was to determine if febuxostat could prevent tumor lysis syndrome (TLS) in children who received induction chemotherapy for hematologic malignancies. PATIENTS AND METHODS: A retrospective analysis was performed in 45 pediatric patients with hematological malignancies who received febuxostat (10 mg daily, n=20) or allopurinol (300 mg/m2 daily, n=25) as a prophylaxis for TLS. RESULTS: A significant decrease of serum uric acid (UA) level was observed in patients with febuxostat over the first 2 days (6...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28335813/tumor-lysis-syndrome-in-an-extraskeletal-osteosarcoma-a-case-report-and-review-of-the-literature
#2
REVIEW
Vito Emanuele Catania, Michele Vecchio, Michele Malaguarnera, Roberto Madeddu, Giulia Malaguarnera, Saverio Latteri
BACKGROUND: This case report describes a spontaneous tumor lysis syndrome due to a rare solid tumor. CASE PRESENTATION: A 65-year-old white woman had tumor lysis syndrome, which represent a dangerous oncological emergency. This syndrome occurs usually with a hematological tumor, but in this case our patient had a solid tumor, which was a rare extraskeletal osteosarcoma, localized in her pelvic region. She also had lung metastases and bilateral hydronephrosis. After spontaneous tumor lysis syndrome, she had acute renal insufficiency, which was treated with hemodialysis and successively with rasburicase, Kayexalate (sodium polystyrene sulfonate), and febuxostat...
March 24, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27955822/febuxostat-associated-eosinophilic-polymyositis-in-marginal-zone-lymphoma
#3
Georges Chahine, Khalil Saleh, Claude Ghorra, Nathalie Khoury, Nadine Khalife, Fouad Fayad
Febuxostat is an orally administered selective inhibitor of xanthine oxidase approved for the treatment of gout and prevention of tumor lysis syndrome. It is a relatively safe medication. Hypersensitivity reactions associated with the use of febuxostat are quite rare with only one reported case of DRESS syndrome. Recently, two case reports of rhabdomyolysis following the initiation of febuxostat were published. We hereby present the first case of rhabdomyolysis with hypereosinophilia following the administration of febuxostat to a 50-year-old patient newly diagnosed with marginal zone lymphoma...
March 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/27641217/the-efficacy-of-febuxostat-10-mg-for-the-prevention-of-hyperuricemia-associated-with-tumor-lysis-syndrome-tls-in-japanese-patients-with-non-hodgkin-s-lymphoma%C3%A2
#4
Takeo Yasu, Shunsuke Kobayashi, Mai Horii, Yosuke Kurokawa
Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency. The control of serum uric acid level (UA) is important for prevention of TLS. Febuxostat has demonstrated its superiority over allopurinol in decreasing UA level. We retrospectively evaluated the efficacy of febuxostat 10 mg in prevention of hyperuricemia associated with TLS (HU-TLS) in 12 patients with non-Hodgkin's lymphoma (NHL). Mean UA levels were found to significantly decrease (p = 0.003). HU-TLS was prevented in all patients. Thus, febuxostat 10 mg is effective in prevention of HU-TLS...
December 2016: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27017611/efficacy-and-safety-of-febuxostat-for-prevention-of-tumor-lysis-syndrome-in-patients-with-malignant-tumors-receiving-chemotherapy-a-phase-iii-randomized-multi-center-trial-comparing-febuxostat-and-allopurinol
#5
RANDOMIZED CONTROLLED TRIAL
Kazuo Tamura, Yasukazu Kawai, Toru Kiguchi, Masataka Okamoto, Masahiko Kaneko, Makoto Maemondo, Kenichi Gemba, Katsumichi Fujimaki, Keita Kirito, Tetsuya Goto, Tomoaki Fujisaki, Kenji Takeda, Akihiro Nakajima, Takanori Ueda
BACKGROUND: Control of serum uric acid (sUA) levels is very important during chemotherapy in patients with malignant tumors, as the risks of tumor lysis syndrome (TLS) and renal events are increased with increasing levels of sUA. We investigated the efficacy and safety of febuxostat, a potent non-purine xanthine oxidase inhibitor, compared with allopurinol for prevention of hyperuricemia in patients with malignant tumors, including solid tumors, receiving chemotherapy in Japan. METHODS: An allopurinol-controlled multicenter, open-label, randomized, parallel-group comparative study was carried out...
October 2016: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/26216382/florence-a-randomized-double-blind-phase-iii-pivotal-study-of-febuxostat-versus-allopurinol-for-the-prevention-of-tumor-lysis-syndrome-tls-in-patients-with-hematologic-malignancies-at-intermediate-to-high-tls-risk
#6
RANDOMIZED CONTROLLED TRIAL
M Spina, Z Nagy, J M Ribera, M Federico, I Aurer, K Jordan, G Borsaru, A S Pristupa, A Bosi, S Grosicki, N L Glushko, D Ristic, J Jakucs, P Montesinos, J Mayer, E M Rego, S Baldini, S Scartoni, A Capriati, C A Maggi, C Simonelli
BACKGROUND: Serum uric acid (sUA) control is of key relevance in tumor lysis syndrome (TLS) prevention as it correlates with both TLS and renal event risk. We sought to determine whether febuxostat fixed dose achieves a better sUA control than allopurinol while preserving renal function in TLS prevention. PATIENTS AND METHODS: Patients with hematologic malignancies at intermediate to high TLS risk grade were randomized to receive febuxostat or allopurinol, starting 2 days before induction chemotherapy, for 7-9 days...
October 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26137024/reduced-administration-of-rasburicase-for-tumor-lysis-syndrome-a-single-institution-experience
#7
Mihoko Takai, Takahiro Yamauchi, Yasufumi Matsuda, Katsunori Tai, Satoshi Ikegaya, Shinji Kishi, Yoshimasa Urasaki, Akira Yoshida, Hiromichi Iwasaki, Takanori Ueda
In the present study, the dosage and duration of rasburicase administration were retrospectively evaluated for the ability to control the serum uric acid (S-UA) level in 13 patients diagnosed with hematological malignancies and tumor lysis syndrome (TLS), or those at risk of developing TLS, at the University of Fukui Hospital. At the time of diagnosis, seven patients already exhibited laboratory TLS, and three demonstrated clinical TLS. All patients received rasburicase in addition to chemotherapy agents. The median dose was 0...
May 2015: Oncology Letters
https://www.readbyqxmd.com/read/25503162/febuxostat-for-management-of-tumor-lysis-syndrome-including-its-effects-on-levels-of-purine-metabolites-in-patients-with-hematological-malignancies-a-single-institution-s-pharmacokinetic-and-pilot-prospective-study
#8
Mihoko Takai, Takahiro Yamauchi, Miyuki Ookura, Yasufumi Matsuda, Katsunori Tai, Shinji Kishi, Akira Yoshida, Hiromichi Iwasaki, Toru Nakamura, Takanori Ueda
BACKGROUND/AIM: Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, and control of serum uric acid level (S-UA) is most important. In this single-institution, short-term and pilot prospective study, the efficacy of a new xanthine oxidase inhibitor, febuxostat, as an alternative to conventional allopurinol, including its effects on hypoxanthine and xanthine, was evaluated in 10 consecutive patients with hematological malignancies at intermediate risk for TLS. PATIENTS AND METHODS: Febuxostat at 40 mg (n=7) or 60 mg (n=3) daily was administered according to renal function, and induction chemotherapy was started within 24 h...
December 2014: Anticancer Research
https://www.readbyqxmd.com/read/25279293/hypouricemic-effect-and-safety-of-febuxostat-used-for-prevention-of-tumor-lysis-syndrome
#9
Koichiro Maie, Yasuhisa Yokoyama, Naoki Kurita, Hideto Minohara, Shintaro Yanagimoto, Yuichi Hasegawa, Masato Homma, Shigeru Chiba
PURPOSE: We evaluated the efficacy and safety of febuxostat, a non-purine xanthine oxidase inhibitor, used for prevention of hyperuricemia associated with tumor lysis syndrome (TLS). METHODS: Records of adult patients with newly diagnosed or relapsed hematologic malignancies who received febuxostat within 7 days before initiation of chemotherapy were retrieved retrospectively at a single institute. The changes in serum uric acid levels from before and 7 days after initiation of febuxostat were evaluated and compared with the historical control group of patients who received allopurinol...
2014: SpringerPlus
https://www.readbyqxmd.com/read/25202361/controlling-serum-uric-acid-using-febuxostat-in-cancer-patients-at-risk-of-tumor-lysis-syndrome
#10
Mihoko Takai, Takahiro Yamauchi, Kei Fujita, Shin Lee, Miyuki Ookura, Shinji Kishi, Yoshimasa Urasaki, Akira Yoshida, Hiromichi Iwasaki, Takanori Ueda
Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, in which control of serum uric acid (S-UA) levels is important. S-UA-lowering efficacy of a new xanthine oxidase inhibitor, febuxostat, was retrospectively evaluated in seven patients with hematological malignancies who were at an intermediate risk of developing TLS. A 10-mg dose of febuxostat was initiated and chemotherapy was started within 24 h of administering the first dose of febuxostat. Febuxostat was continued until at least day 7 of chemotherapy treatment...
October 2014: Oncology Letters
https://www.readbyqxmd.com/read/17525897/tumor-lysis-syndrome
#11
REVIEW
Ramon V Tiu, Stavros E Mountantonakis, Andrew J Dunbar, Martin J Schreiber
Tumor lysis syndrome (TLS) is an important metabolic disorder frequently encountered in the management of a variety of cancers including lymphoma, leukemia, and neuroblastoma. Delayed recognition can result in a variety of biochemical abnormalities resulting in life-threatening complications such as renal failure, arrhythmias, and seizures. Identification of high-risk patients and early recognition of the syndrome is crucial in the early institution of appropriate prophylaxis and treatment. Recent advances in the understanding of urate metabolism, development of new urate-lowering drugs, and the application of biomarkers, calculation methods, and prognostic models to identify high-risk patients will pave the way in improving the management of TLS...
June 2007: Seminars in Thrombosis and Hemostasis
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"